Bratisl Lek Listy. 2023;124(6):466-470. doi: 10.4149/BLL_2023_071.
The coronavirus disease 2019 (COVID-19) causes acute respiratory illness and multi-organ failure. The critical roles of magnesium in human health suggest that it could have an active role in the prevention and treatment of COVID-19. We measured magnesium levels in hospitalized COVID-19 patients concerning disease progression and mortality.
This study was conducted in 2321 hospitalized COVID-19 patients. Clinical characteristics from each patient were recorded, and blood samples were collected from all patients upon their first admission to the hospital to determine serum magnesium levels. Patients were divided into two groups based on discharge or death. The effects of magnesium on death, severity, and hospitalization duration were estimated by crude and adjusted odds ratio using Stata Crop (version 12) software.
Mean magnesium levels in patients who died were higher than in discharged patients (2.10 vs 1.96 mg/dl, p 0.05).
We found no relation between hypomagnesaemia on COVID-19 progression, although hypermagnesaemia could affect COVID-19 mortality (Tab. 4, Ref. 34).
2019 年冠状病毒病(COVID-19)可引起急性呼吸道疾病和多器官衰竭。镁在人类健康中的重要作用表明,它可能在 COVID-19 的预防和治疗中发挥积极作用。我们检测了住院 COVID-19 患者的镁水平,以了解疾病进展和死亡率。
这项研究纳入了 2321 例住院 COVID-19 患者。记录每位患者的临床特征,并在每位患者首次入院时采集血样以确定血清镁水平。根据出院或死亡将患者分为两组。使用 Stata Crop(版本 12)软件,通过未调整和调整后的优势比估计镁对死亡、严重程度和住院时间的影响。
死亡患者的平均镁水平高于出院患者(2.10 对 1.96mg/dl,p>0.05)。
我们未发现低镁血症与 COVID-19 进展之间存在关系,尽管高镁血症可能会影响 COVID-19 的死亡率(表 4,参考文献 34)。